ExperimentalAbout Shaker A. Mousa, Ph.D., MBA, FACC, FACB
PRI
Executive Vice President and Chairman Shaker A. Mousa, Ph.D., MBA, FACC,
FACB, has demonstrated throughout his distinguished career the ability
to bring novel concepts from the bench to the bedside, along with great
vision in selecting the right target. He has demonstrated the ability
to plan strategically and implement tactical measures in achieving the
required goals and objectives.
Dr. Mousa came to Albany College of Pharmacy in 2002 following a career of more than 17 years as a principal research scientist at DuPont Pharmaceuticals Co. He is a tenured professor at the College in addition to his leadership role with PRI.
Dr. Mousa also is a visiting scholar at The Johns Hopkins University and holds academic appointments of adjunct professor in the Department of Medicine at Temple University's Sol Sherry Thrombosis Research Center, the Department of Medicine of the State University of New York at Buffalo and the Department of Pharmacology of the University of Pennsylvania.
Among
Dr. Mousa's professional accomplishments are his contributions to several
patents - he holds 30 U.S. patents, including six filed in 2004 and 2005,
and more than 200 foreign patents - and to the discovery and development
of novel anti-platelet, anti-thrombotic therapies, non-invasive myocardial
perfusion and thrombus imaging agents. His work has been reported in more
than 600 publications. Additionally, he contributed to the discovery and
development of the following products and clinical candidates:
- Cardiolite R (Tc99m sestamibi RP30, non-invasive myocardial
perfusion imaging agent)
- Marluma (Tc99m sestamibi RP30, for breast cancer detection)
- DMP444 (Tc99m platelet GPIIb/IIIa antagonist for non-invasive
thrombus imaging agent in venous and arterial thromboembolic disorders)
- Roxifiban (DMP754, oral anti-platelet/anti-thrombotic agent for the prevention and treatment of coronary, carotid and peripheral artery thromboembolic disorders).
Dr. Mousa also was involved in the discovery of novel site-directed anti-alpha v beta 3 tumor radiotherapy and imaging, as well working on defining novel angiogenesis inhibitors. He also was involved in the discovery of novel pharmacological aspects of heparin and low-molecular-weight heparin, and contributed to the advancement of several key concepts, including the synergistic benefits of GPIIb/IIIa antagonists in combination with thrombolytics; the role of integrin alpha 5 beta 1 in angiogenesis and bacterial invasion of human host cells; and the role of fibrinolytic components such as kininogen in angiogenesis.
Dr. Mousa's current research interests include (see also scholarly activity and biosketch below):
- Adhesion molecules in health and diseases
- Novel therapeutic and diagnostic targets
- Treatment and prevention of ischemic and coronary artery diseases
- Angiogenesis modulation, vascular and tissue remodeling, and novel anti-platelet, anti-thrombotic and anti-ischemic therapies
Dr. Mousa received a Ph.D. in Pharmacology from The Ohio State University, completed postdoctoral research in Cardiovascular Pharmacology at the University of Kentucky and earned his MBA from Widener University.
A native of Alexandria, Egypt, he received his B.Pharm. and M.Sc. degrees from Alexandria University. He was elected a fellow of the American College of Cardiology (FACC) and a fellow of the National Academy of Clinical Biochemistry (FACB), and is a member of several national and international societies. He was recently awarded grants through the U.S. Department of Defense and the National Institute of Health.
In addition, Dr. Mousa serves on the editorial boards and as a reviewer for a number of scientific and medical journals, including Cardiovascular Drug Review, Atherosclerosis,Thrombosis & Vascular Biology, Circulation, Lab Investigation, JCI, JBC and Current Drugs.
Pharmaceutical Research Institute
at Albany College of Pharmacy
1 Discovery Drive, Rensselaer, NY 12144
518-694-7575, fax 518-694-7567